首页> 外文期刊>Patient Safety in Surgery >Monitoring of liver function in a 73-year old patient undergoing ‘Associating Liver Partition and Portal vein ligation for Staged hepatectomy’: case report applying the novel liver maximum function capacity test
【24h】

Monitoring of liver function in a 73-year old patient undergoing ‘Associating Liver Partition and Portal vein ligation for Staged hepatectomy’: case report applying the novel liver maximum function capacity test

机译:监测一名73岁接受“肝分割和门静脉结扎术联合分期肝切除术”患者的肝功能:应用新型肝最大功能检测的病例报告

获取原文
       

摘要

Background The two-stage liver resection combining in situ liver transection with portal vein ligation, also referred to as ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy), has been described as a promising method to increase the resectability of liver tumors. However, one of the most important issues regarding the safety of this procedure is the optimal timing of the second stage at the point of sufficient hypertrophy of the future liver remnant. The recently developed liver maximum function capacity test (LiMAx) can be applied to monitor the liver function postoperatively and hence could be a useful tool for decision-making regarding the timing of the second stage of ALPPS. Case presentation A 73-year-old female patient presented with metachronous colorectal liver metastasis comprising the complete right liver lobe as well as segment IV. Due to an insufficient future liver remnant (19.3?%; segments II and III of the liver) and a low future liver remnant:body weight ratio (0.28?%) the decision was made to perform an ALPPS-procedure in order to avoid development of postoperative small-for-size syndrome. Despite a formally sufficient increase of the FLR to 30.8?% within 7?days after the first step of ALPPS, the liver function was seen to only slowly increase as expressed by a LiMAx value of 245?μg/h/kg (baseline of 282?μg/h/kg prior to surgery). By means of the LiMAx test, sufficient increase of liver function eventually was detected by postoperative day 11 (LiMAx value of 371?μg/h/kg; FLR 35.2?%) so that the second step of ALPPS (completion of hepatectomy) was performed with no signs of liver failure during further clinical course. Conclusion Performing ALPPS we have observed a significant difference between the increase in future liver remnant volume and function applying the LiMAx test. The latter tool thus might proof valuable for application in two-stage liver resection to avoid postoperative small-for-size syndrome.
机译:背景技术将原位肝横断与门静脉结扎相结合的两阶段肝切除术也被称为ALPPS(分期肝切除术的联合肝分区和门静脉结扎),是增加肝肿瘤可切除性的一种有前途的方法。但是,有关此过程安全性的最重要问题之一是,在未来肝残余物足够肥大时,第二阶段的最佳时机。最近开发的肝脏最大功能能力测试(LiMAx)可以用于监测术后肝功能,因此可以作为有关ALPPS第二阶段时间的决策的有用工具。病例介绍一名73岁的女性患者出现了异时性大肠肝转移,包括完整的右肝叶以及IV段。由于将来的肝残留量不足(19.3%;肝脏的第II和III段)并且未来的肝残留物/体重比较低(0.28%),因​​此决定执行ALPPS程序以避免发展术后小型综合征。尽管在ALPPS第一步后的7天之内,FLR的形式充分增加到30.8%,但肝脏功能仅以245?μg/ h / kg的LiMAx值表示缓慢增加(基线为282) ?μg/ h / kg(手术前)。通过LiMAx试验,术后第11天最终检测到肝功能充分增强(LiMAx值为371?μg/ h / kg; FLR 35.2%),因此进行了第二步ALPPS(肝切除术完成)在进一步的临床过程中没有肝功能衰竭的迹象。结论在进行ALPPS时,我们已经观察到将来的肝残余量增加和应用LiMAx测试的功能之间存在显着差异。因此,后一种工具可能证明可用于两阶段肝切除术,以避免术后小尺寸综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号